Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide

Objectives This study aimed at evaluating the efficacy and toxicity of the combination regimen of high‐dose cytarabine, etoposide and cisplatin (HAEP) in adult patients with high‐risk relapsed or refractory acute myeloid leukaemia (AML). Methods From January 2001 to December 2012, 49 relapsed or refractory AML patients [36 men; 13 women; median age, 42 (range, 18–71) yr; patients aged >60 yr, 8] were treated with HAEP [high‐dose cytarabine (2 g/m2), etoposide (100 mg/m2) and cisplatin (20 mg/m2) for five alternative days] as salvage therapy. Patients who had the first relapse at